ReviewEpigenomics2016
DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.
Review in Epigenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Frontiers in oncology · 2024Pooled it
- DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: a systematic review of paired samples.International journal of colorectal disease · 2021Pooled it
- The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis.PloS one · 2018Pooled it
- Methylation-Associated Differentiation Features Define Biological and Prognostic Heterogeneity in CMS4 Colorectal Cancer.International journal of molecular sciences · 2026Article
- A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis.Cancers · 2021Review
- Article
- Diagnosis and prognostic value of C-X-C motif chemokine ligand 1 in colon adenocarcinoma based on The Cancer Genome Atlas and Guangxi cohort.Journal of Cancer · 2021Article
- Potential lncRNA Biomarkers for HBV-Related Hepatocellular Carcinoma Diagnosis Revealed by Analysis on Coexpression Network.BioMed research international · 2021Article
- Hypomethylation of GDNF family receptor alpha 1 promotes epithelial-mesenchymal transition and predicts metastasis of colorectal cancer.PLoS genetics · 2020Article
- Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.Cancer gene therapy · 2020Article
- Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2020Article
- Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression.BMC cancer · 2020Article
- Epigenetic Aging: More Than Just a Clock When It Comes to Cancer.Cancer research · 2020Review
- Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan.World journal of gastroenterology · 2020Article
- The Protective Effect of Polyphenols for Colorectal Cancer.Frontiers in immunology · 2020Review
- Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.BMC bioinformatics · 2019Article
- Identification of Cross Talk between FoxM1 and RASSF1A as a Therapeutic Target of Colon Cancer.Cancers · 2019Article
- Epigenetic IVD Tests for Personalized Precision Medicine in Cancer.Frontiers in genetics · 2019Review
- STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway.Journal of experimental & clinical cancer research : CR · 2018Article
- Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.Seminars in cancer biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Aberrant DNA methylation is frequently detected in gastrointestinal tumors, and can therefore potentially be used to screen, diagnose, prognosticate, and predict colorectal cancers (CRCs). Although colonoscopic screening remains the gold standard for CRC screening, this procedure is invasive, expensive, and suffers from poor patient compliance. Methylated DNA is an attractive choice for a biomarker substrate because CRCs harbor hundreds of aberrantly methylated genes. Furthermore, abundance in extracellular environments and resistance to degradation and enrichment in serum, stool, and other noninvasive bodily fluids, allows quantitative measurements of methylated DNA biomarkers. This article describes the most important studies that investigated the efficacy of serum- or stool-derived methylated DNA as population-based screening biomarkers in CRC, details several mechanisms and factors that control DNA methylation, describes a better use of prevailing technologies that discover novel DNA methylation biomarkers, and illustrates the diversity of demethylating agents and their applicability toward clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.